Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos ...

An investigational immunomodulator gel significantly improved malodor and measures related to pain and quality of life for ...

Advancements in the form of recent approvals and an evolving pipeline landscape in dermatology will bolster Leo’s chance of ...

USA: Researchers have found in a new study that Clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% (CAB) ...

The minimally dilutive funding will accelerate Pelthos’ highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum ...

In a study published in June 2024, they took male mice with testosterone-driven hair loss and removed the fur from their ...

You’ll receive a four-month supply of serums and replacement tips with the hydrafacial device by shopping this added value ...

Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis. In this extension (Cohort 3) of the ...

In experiments, the researchers used mice with testosterone-induced hair loss. The mice were divided into four groups: a ...

As of Friday, December 26, Sol-Gel Technologies Ltd.’s SLGL share price has dipped by 5.05%, which has investors questioning if this is right time to buy.

As of Friday, January 09, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 37.28%, which has investors ...